Is there a standard chemotherapeutic regimen for hormone-refractory prostate cancer? Present and future approaches in the management of the disease

Tumori

Volumn 89, Issue 4, 2003, Pages 349-360

  Di Lorenzo, Giuseppe ^b   Autorino, Riccardo ^b   De Laurentiis, Michele ^b   Bianco, Roberto ^b   Lauria, Rossella ^b   Giordano, Antonio ^b   De Sio, Marco ^b   D'Armiento, Massimino ^b   Bianco, Angelo Raffaele ^b   De Placido, Sabino ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b NONE

Author keywords

Chemotherapy; Hormone refractory prostate cancer; Treatment

Indexed keywords

ANALGESIC AGENT; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GLUCOCORTICOID; HYDROCORTISONE; IRINOTECAN; MITOMYCIN C; MITOXANTRONE; NAVELBINE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT ALPHA2A INTERFERON; TAXANE DERIVATIVE; TEGAFUR; TOPOTECAN; UNINDEXED DRUG; URACIL; VINBLASTINE; VINCA ALKALOID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASTHENIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; HUMAN; HYPERCOAGULABILITY; LEUKOPENIA; MALE; MYALGIA; NAUSEA; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PAIN; PALLIATIVE THERAPY; PARESTHESIA; PERIPHERAL NEUROPATHY; PROSTATE CANCER; REVIEW; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; VASCULAR DISEASE; VOMITING;

EID: 0142073762     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160308900402     Document Type: Review

References (97)

1. Scher HI, Steineck G, Kelly WK: Hormone-refractory (D3) prostate cancer: refining the concept. Urology, 46: 142-148, 1995.
2. Eisenberger MA, Simon R, O'Dwyer PJ, Wittes RE, Friedman MA: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol, 3: 827-835, 1985.
3. Yagoda A, Petrylak DP: Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer, 71 (suppl): 1098-1099, 1993.
4. Hudes G, Nathan F, Khater C, Has N, Cornfield M, Giantonio B, Greenberg R, Gomella L, Litwin S, Ross E, Roethke S, McAleer C: Phase II trial of 96 hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol, 15: 3156-3163, 1993.
5. Trivedi C, Redaman B, Flaherty LE, Kucuk O, Du W, Heilbrun LK, Hussain M: Weekly one-hour infusion of paclitaxel. Clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer, 89: 431-436, 2000.
6. Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G: Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer. Urology, 58: 59-64, 2001.
7. Ferrari AC, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, Mandeli J, Muggia F: A phase I/II study of weekly paclitaxel and 3 days of high dose oral estramustine in patients with hormone refractory prostate carcinoma. Cancer, 91: 2039-2045, 2001.
8. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V: Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol, 10: 33-38, 1999.
9. Petrylak DP, MacArthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 17: 958-967, 1999.
10. Petrylak DP, MacArthur RB, O'Connor J, Shelton G, Weitzman A, Judge T, England-Owen C, Zuech N, Pfaff C, Newhouse J, Bagiella E, Heitjan D, Sawczuk I, Benson M, Olsson C: Phase I/II studies of docetaxel (taxotere) combined with estramustine in men with hormone refractory prostate cancer. Semin Oncol, 26 (5 suppl 17): 28-33, 1999.
11. Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang N: Phase II study of docetaxel, estramustine and low-dose hydrocortisone in men with hormone refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol, 19: 2509-2516, 2001.
12. Sinibaldi V, Carducci M, Laufer M, Eisenberger M: Preliminary evaluation of short course of estramustine phosphate and docetaxel (taxotere) in hormone refractory prostate cancer. Semin Oncol, 26 (5 suppl 17): 45-48, 1999.
13. Sitka Copur M, Ledakis P, Lynch J, Hauke R, Tarantolo S, Bolton M, Norvell M, Muhvic J, Hake L, Wendt J: Weekly docetaxel and estramustine in patients with hormone- refractory prostate cancer. Semin Oncol, 28 (4 suppl 15): 16-21, 2001.
14. Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ: Phase II trial of oral estramustine, oral etoposide and intravenous paclitaxel in hormone refractory prostate cancer. J Clin Oncol, 17: 1664-1671, 1999.
15. Hussain M, Petrylak D, Fisher E, Tangen C, Crawford D: Docetaxel (taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916. Semin Oncol, 26 (5 suppl 17): 55-60, 1999.
16. Oudard S, Banu E, Vannetzel JM, Beuzeboc P, Dourthe LM, Voog E, Hardy AC, Kamioner D, Coscas I, Chauvet B: Results of phase II randomized trial of DEP (two schedules) versus mitoxantrone and prednisone in patients with HRPC (abstract 3250). Ann Oncol, 13 (suppl 5); ESMO Congress 2002.
17. Attivissimo LA, Fetten JV, Kreis W: Symptomatic improvement associated with combined estramustine and vinblastine chemotherapy for metastatic prostate cancer. Am J Clin Oncol, 19: 581-583, 1996.
18. Hudes G, Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone refractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial. J Clin Oncol, 17: 3160-3166, 1999.
19. Albrecht W, Horenblas S, Marechal JM, Mikisch A, Seretta V, Cassetta G, van Poppel H, Kalman S, Sylvester R: EMP versus EMP/VBL. Chemotherapie beim hormonrefraktaren Prostatakrazinom. Urology A, 37: 32-35, 1998.
20. Fields-Jones S, Koletsky A, Wilding G, O'Rourke M, Eckardt J, Yates B, McGuirt C, Burris HA III: Improvement in clinical benefit with vinorelbine in the treatment of hormone refractory prostate cancer: a phase II trial. Ann Oncol, 10: 1307-1310, 1999.
21. Oudard S, Caty A, Humblet Y, Beauduin M, Suc E, Piccart M, Rolland F, Fumoleau P, Bugat R, Houyau P, Monnier A, Sun X, Montcuquet P, Breza J, Novak J, Gil T, Chopin D: Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol, 12: 847-852, 2001.
22. Carles J, Domenech M, Gelabert-Mas A, Nogue M, Tabernero M, Arcusa A, Guasch I, Miguel A, Ballesteros J, Fabregat X: Phase II study of estramustine and vinorelbine in hormone refractory prostate carcinoma patients. Acta Oncol, 37: 187-191, 1998.
23. Colleoni M, Graiff C, Vicario G, Nelli P, Sgarbossa G, Pancheri F, Manente P: Phase II study of estramustine, oral etoposide, and vinorelbine in hormone refractory prostate cancer. Am J Clin Oncol, 20: 383-386, 1997.
24. Benson RC, Hartley-Asp B: Mechanisms of action and clinical uses of estramustine. Cancer Invest, 8: 375, 1990.
25. Iversen P, Rasmussen F, Asmussen C, Christensen IBJ, Eickhoff J, Klarskov P, Larsen E, Mogensen P, Mommsen S, Rosenkilde P: Estramustine phosphate versus placebo as second line treatment after orchiectomy in patients with metastatic prostate cancer: DAPROCA study 9002. J Urol, 157: 929-934, 1997.
26. Pienta KJ, Redman BG, Hussain M, Cummings G, Esper PS, Appel C, Flaherty LE: Phase II of oral estramustine and oral etoposide in hormone refractory adenocarcinoma of the prostate. J Clin Oncol, 12: 2005-2012, 1994.
27. Pienta KJ, Redman BG, Bandekar R, Strawderman M, Cease K, Esper PS, Naik H, Smith DC: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology, 50: 401-407, 1997.
28. Pienta KJ, Fisher EI, Eisenberger MA, Mills GM, Goodwin JW, Jones JA, Dakhil SR, Crawford ED, Hussain MH: A phase II trial of estramustine and etoposide in hormone refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9407). Prostate, 46: 257-261, 2001.
29. Dimopoulos MA, Panopoulos C, Bamia C, Deliveliotis C, Alivizatos G, Pantazopoulos D, Costantinidis C, Kostakopoulos A, Kastriotis I, Zervas A, Aramantinos G, Dimopoulos C: Oral estramustine and oral etoposide for hormone refractory prostate cancer. Urology, 50: 754-758, 1997.
30. Bracarda S, Tonato M, Rosi P, Deangelis V, Mearini E, Cesaroni S, Fornetti P, Porena M: Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma. Cancer, 88: 1438-1444, 2000.
31. Small EJ, Srinivas S, Egan B, McMillan A, Readern T: Doxorubicin and dose-escalated cyclophosphamide with granulocyte colony-stimulating factor for the treatment of hormone resistant prostate cancer. J Clin Oncol, 14: 1617-1625, 1996.
32. Culine S, Kattan J, Zanetta S, Thèodore C, Fizazi K, Droz JP: Evaluation of estramustine phosphate combined with weekly doxorubicin in patients with androgen-independent prostate cancer. Am J Clin Oncol, 21: 470-474, 1998.
33. Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE: Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer. Am J Clin Oncol, 23: 589-592, 2000.
34. Hernes EH, Fossa SD, Vaage S, Ogreid P, Heilo A, Paus E: Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study. Br J Cancer, 76: 93-99, 1997.
35. Recchia F, Sica G, De Filippis S, Rosselli M, Pompili PL, Rea S: Phase II study of epirubicin, mytomicin C and 5-fluoruracil in hormone-refractory prostatic carcinoma. Am J Clin Oncol, 24: 232-236, 2001.
36. Moore MJ, Osoba D, Murphy K, Tannock IF, Armitage A, Findlay B, Coppin C, Neville A, Venner P, Wilson J: Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol, 12: 689-694, 1994.
37. Raghavan D, Coorey G, Rosen M, Page J, Farebrother T: Management of hormone resistant prostate cancer: an Australian trial. Semin Oncol, 23 (suppl 14): 20-23, 1996.
38. Otto T, Rembrink K, Goepel M, Krege S, Meyer-Schwiekerath M, Rubben H: Therapy of hormone refractory prostate carcinoma with mitoxantrone. A clinical phase II study. Urologe A, 35: 142-145, 1996.
39. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville A, Moore MJ, Armitage G, Wilson J, Venner P, Coppin C, Murphy K: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756-1764, 1996.
40. Kantoff P, Halabi S, Conaway M, Picus J, Kirschner J, Hars V, Trump D, Winner E, Vogelzang N: Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol, 17: 2506-2513, 1999.
41. Levine EG, Halabi S, Roberts JD, Kaplan EB, Rago R, Atkins JN, Vogelzang NJ: Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. Cancer, 94: 665-672, 2002.
42. Huan SD, Stewart DJ, Aitken SE, Segel R, Yau JC: Combination of epirubicin and cisplatinum in hormone refractory metastatic prostate cancer. Am J Clin Oncol, 22: 471-474, 1999.
43. Veronesi A, Re GL, Foladore S, Merlo A, Giuliotto N, Talamini R, Monfardini S: Multidrug chemotherapy in the treatment of non-elderly patients with hormone refractory prostatic carcinoma. Eur Urol, 29: 434-438, 1996.
44. Miglietta L, Cannobbio L, Boccardo F: Assessment of response to carboplatin in patients with hormone refractory prostate cancer: a critical analysis of drug activity. Anticancer Res, 15: 2825-2828, 1995.
45. Jungi WF, Bernhard J, Hurniy C, Schmitz SF, Hanselmann S, Gusset H, Pestalozzi D, Goldhirsch A: Effect of carboplatin on response and palliation in hormone -refractory prostate cancer. Swiss Group for Clinical Cancer Research (SAKK). Support Care Cancer, 6: 462-468, 1998.
46. Fuse H, Muraishi Y, Fujishiro Y, Katayama T: Etoposide, epirubicin and carboplatin in hormone refractory prostate cancer. Int Urol Nephrol, 28: 79-85, 1996.
47. Berlin JD, Propert KJ, Trump D, Wilding G, Hudes G, Glick J, Burch P, Keller A, Loehrer P: 5-Fluorouracil and leucovorin therapy in patients with hormone refractory prostate cancer: an Eastern Cooperative Oncology Group phase II study (E1889). Am J Clin Oncol, 21: 171-176, 1998.
48. Atkins JN, Muss HB, Case LD, Richards F, Grote T, McFarland J: Leucovorin and high-dose fluorouracil in metastatic prostate cancer. A phase II trial of the Piedmont Oncology Association. Am J Clin Oncol, 19: 23-25, 1996.
49. Breul J, Jakse G, Forster G, Lampel A, Rohani A, Hartung R: 5-Fluorouracil versus folinic acid and 5-fluorouracil in advanced, hormone resistant prostate cancer: a prospective randomized pilot trial. Eur Urol, 32: 280-283, 1997.
50. Shinohara N, Demura T, Matsumura K, Toyoda K, Kashiwagi A, Nagamori S, Ohmuro H, Ohzono S, Koyanagi T: 5-Fluorouracil and low-dose recombinant interferon-alpha-2a in patients with hormone refractory adenocarcinoma of the prostate. Prostate, 35: 56-62, 1998.
51. Morant R, Bernhard J, Maibach R, Borner M, Fey MF, Thurlimann B, Jacky E, Trinkler F, Bauer J, Zulian G, Hanselmann S, Hurny C, Hering F: Response and palliation in a phase II trial of gemcitabine in hormone refractory metastatic carcinoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol, 11: 183-188, 2000.
52. Maulard-Durdux C, Dufour B, Hennequin C, Chrètien Y, Delanian S, Housset M: Phase II study of oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients. Cancer, 77: 1144-1148, 1996.
53. Nishimura K, Nonomura N, Ono Y, Nozawa M, Fukui T, Harada Y, Imazu T, Takaha N, Sugao H, Miki T, Okuyama A: Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer. Oncology, 60: 49-54, 2001.
54. Hudes GR, Kosierowski R, Greenberg R, Ramsey HE, Fox SC, Ozolos RF, Mc Aleer CA, Giantonio BJ: Phase II study of topotecan in metastatic hormone refractory prostate cancer. Invest New Drugs, 13: 235-240, 1995.
55. Reese DM, Tchekmedyians S, Chapman Y, Prager D, Rosen PJ: A phase II trial of irintecan in hormone refractory prostate cancer. Invest New Drugs, 16: 353-359, 1998.
56. Jongsma J, Oomen MHA, Noorddzij MA, Schroder FH, van Steenbrugge GJ: Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate, 42: 34-44, 2000.
57. Kadmon D, Thompson T, Lynch G, Scardino P: Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol, 146: 358-364, 1991.
58. Krijnen JL, Bongdanowicz J, Mulder PG, van der Kwast TH. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol, 158: 171-174, 1997.
59. Maulard C, Rechaud P, Droz JP, Jessueld D, Dufour-Esquerrè F, Housset M: Phase I/II study of the somatostatin analogue lanreotide in hormone refractory prostate cancer. Cancer Chemother Pharmacol, 36: 259-262, 1995.
60. Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O: A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone refractory prostate cancer. Cancer, 75: 2159-2164, 1995.
61. Dizeyi N, Konrad L, Bjartell, Wu H, Hansson J, Helboe L, Abrahamsson PA. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol Oncol, 7: 91-98, 2002.
62. Koutsilieris M, Mitsiades C, Dimopoulos T, Ioannidis A, Ntounis A, Lambou T: A combination therapy of dexamethasone and somatostatin analog reintroduces objective responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrinol Metab, 86: 5729-5736, 2001.
63. Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich M, Cassidy J, Kohler DR, Trepel J, Linehan M: Suramin: a novel growth factor antagonist with activity in hormone refractory metastatic prostate cancer. J Clin Oncol, 10: 881-889, 1992.
64. Eisenberger MA, Sinibaldi VJ, Reyno LM, Sridhara R, Jodrell DI, Zuhowski EG, Tkaczuk KH, Lowitt MH, Hemady RK, Jacobs SC, VanEcho D, Egorin MJ: Phase I clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone refractory prostate cancer. J Clin Oncol, 13: 2174-2186, 1995.
65. Kelly KW, Curley T, Leibertz C, Dnistrian A, Schwartz M, Scher HI: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol, 13: 2208-2213, 1995.
66. Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O: Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer, 6: 453-462, 1995.
67. Rosen PJ, Mendoza EF, Landaw EM, Mondino B, Graves MC, McBride JH, Turcillo P, deKernion J, Belldegrun A: Suramin in hormone-refractory metastatic prostate cancer: a drug with limited activity. J Clin Oncol, 4: 1626-1636, 1996.
68. Calvo E, Cortes J, Rodriguez J, Sureda M, Beltran C, Rebollo J, Martinez-Monge R, Berian JM, de Irala J, Brugarolas A: Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter phase II study. Cancer, 92: 2435-2443, 2001.
69. Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M: Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol, 18: 1440-1450, 2000.
70. Trump DL, Smith DC, Stiff D, Adedoyin A, Day R, Bahnson RR, Hofecker J, Branch RA: A phase II trial of all-transretinoic acid in hormone refractory prostate cancer: a clinical trial with detailed pharmacokinetic analysis. Cancer Chemother Pharmacol, 39: 349-356, 1997.
71. Culine S, Kramar A, Droz JP, Theodore C: Phase II study of all-trans retinoic acid administered intermittently for hormone refractory prostate cancer. J Urol, 161: 173-175, 1999.
72. Seidmon EJ, Trump DL, Kreis W, Hall SW, Kurman MR, Ouyang SP, Wu J, Kremer AB: Phase I/II dose-escalation study of liarozole in patients with stage D, hormone refractory carcinoma of the prostate. Ann Surg Oncol, 2: 550-556, 1995.
73. Dijkman GA, Fernandez del Moral P, Bruynseels J, De Porre P, Denis L, Debruyne FJM: Liarozole (R75251) in hormone resistant prostate cancer patients. Prostate, 33: 26-31, 1997.
74. Debruyne FJM, Murray R, Fradet Y, Johansson JE, Tyrrell K, Boccardo F, Denis L, Marberger JM, Burne D, Rassweiler J, Vangeneugden T, Bruynseels J, Janssens M, De Porre P: Liarozole, a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate. Urology, 52: 72-81, 1998.
75. Di Lorenzo G, Tortora G, D'Armiento F, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F: Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res, 8: 3838-3844, 2002.
76. Miller K, Raabe N, Trachtenberg J, Trump D, Wilding G, Das-Gupta A: ZD1839, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKi) is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refractory prostate cancer (HRPC) (abst 3270, ESMO Congress). Ann Oncol, 13 (suppl 5): 2002.
77. Souliè P, Trump D, Wilding G, Small E, Das-Gupta A: ZD 1839, an epidermal growth factor tyrosine kinase inhibitor (EGFR-TKi) in combination with docetaxel and estramustine in patients with hormone-refractory prostate cancer (HRPC) (abst 3280, ESMO Congress). Ann Oncol, 13 (suppl 5): 2002.
78. Small EJ, Bok R, Reese DM, Sudilovsky D, Frohlich M: Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer. Semin Oncol, 4 (suppl 15): 71-76, 2001.
79. Tolcher AW: Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone refractory prostate cancer. Semin Oncol, 4 (suppl 15): 67-70, 2001.
80. Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, D'Aloisio S, Tolcher AW: A phase I dose-finding study of combined treatment with an antisense bcl-2 oligonucleotide (genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res, 7: 3920-3927, 2001.
81. Kuenen BC, Rosen L, Smit EF, Parson M, Levi M, Hoekman K, Pinedo M, Giaccone G: Dose finding and pharmacokinetic study of cisplatin, gemcitabine and SU5416 in patients with solid tumors. J Clin Oncol, 20: 1657-1667, 2002.
82. Wu-Wong JR: Endothelin receptor antagonists: past, present and future. Curr Opin Cardiovasc Pulmon Renal Invest Drugs, 1: 346-351, 1999.
83. Usami BA, Shen R, Janeczko M: Methylation of the neutral endopeptidase gene promoter in human prostate cancer. Clin Cancer Res, 6: 1664-1670, 2000.
84. Gohji K, Kitazawa S, Tamada H: Expression of endothelin receptor A associated with prostate cancer progression. J Urol, 165: 1033-1036, 2001.
85. Nelson JB, Chan-Tack K, Hedican SP: Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res, 56: 663-668, 1996.
86. Nelson JB, Nguyen SH, Wu-Wong JR: New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology, 53: 1063-1069, 1999.
87. Opgenorth TJ, Adler AL, Calzadilla SV: Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist. J Pharmacol Exp Ther, 276: 473-481, 1996.
88. Carducci M, Padley RJ, Breul J, Vogelzang, NJ, Zannenberg BA, Daliani, DD, Schulman CC, Nabulsi, AA, Humerickhouse RA, Weinberg MA, Schmitt JL, Nelson JB: Effect of endothelin-A receptor blockade with atrasetan on tumor progression in men with hormone refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol, 21: 679-689, 2003.
89. Crul M, de Klerk GJ, Swart M, Tan H, deGast GC, Beijnen JH, Schellens JHM: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Oncol, 20: 2726-2735, 2002.
90. Tolcher AW, Reyno L, Venner PM, Ernst SD, Moore M, Geary RS, Chi K, Hall S, Walsh W, Dorr A, Eisenhauer E: A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone refractory prostate cancer. Clin Cancer Res, 8: 2530-2535, 2002.
91. Schwartz GK, O'Reilly E, Ilson D, Salz L, Sharma S, Tong W, Maslak P, Stolz M, Eden L, Perkins P, Endres S, Barrazzoul J, Spriggs D, Kelsen D: Phase I study of cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol, 20: 2157-2170, 2002.
92. Song X, Johnson AJ, Tseng PH, Yang YT, Kulp SK, Chen CS: Cyclooxygenase-2: player or spectator in cyclooxygenase-2 inhibitor-induced apoptosis in prostate cancer cells. J Natl Cancer Inst, 94: 585-591, 2002.
93. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes J, Goad, JA, Chen B: A randomized, placebo controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma. J Natl Cancer Inst, 94: 1458-1468, 2002.
94. Crawford ED, Rosenblum M, Ziada AM, Lange PH: Overview: hormone refractory prostate cancer. Urology, 54: 1-7, 2000.
95. Petrylak DP: Chemotherapy for advanced hormone refractory prostate cancer. Urology, 54 (suppl 6A): 30-35, 1999.
96. Smith DC: Chemotherapy for hormone refractory prostate cancer. Urol Clin North Am, 26: 323-331, 1999.
97. Oh WK: Chemotherapy for patients with advanced prostate carcinoma. Cancer, 88: 3015-3021, 2000.